Stock comparison
Genmab A/S
Neurocrine Biosciences
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
GMAB
Genmab A/S
Market cap
$16.47B
Sector
Healthcare
NBIX
Neurocrine Biosciences
Market cap
$15.76B
Sector
Healthcare
Overall winner
Neurocrine Biosciences NBIX
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | GMAB | NBIX | Winner |
|---|---|---|---|
| Warren Buffett | 65C | 68B | NBIX |
| Benjamin Graham | 64C | 78B | NBIX |
| Philip Fisher | 48D | 80A | NBIX |
| Peter Lynch | 25F | 65B | NBIX |
| Joel Greenblatt | 76B | 55C | GMAB |
| Charlie Munger | 68C | 60C | GMAB |
| Terry Smith | 71C | 63D | GMAB |
Side-by-side metrics
| Metric | GMAB | NBIX |
|---|---|---|
| Market cap | $16.47B | $15.76B |
| P/E (TTM) | 6.2x | 22.6x |
| EV/EBIT | 12.0x | 24.7x |
| ROIC (TTM) | 43.78% | 13.68% |
| Gross margin | 93.88% | 98.17% |
| Net margin | 18.23% | 21.55% |
| Revenue CAGR 5y | -18.45% | 26.04% |
| EPS CAGR 5y | -23.48% | 50.0% |
| Debt / Equity | 0.1x | 0.1x |
| Dividend yield | 0.0% | 0.0% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
GMAB leads on
- P/E (TTM)6.2xvs 22.6x+73%
- ROIC (TTM)43.78%vs 13.68%+69%
- EV/EBIT12.0xvs 24.7x+51%
- Debt / Equity0.1xvs 0.1x+38%
NBIX leads on
- Revenue CAGR 5y26.04%vs -18.45%+171%
- EPS CAGR 5y50.0%vs -23.48%+147%
- Net margin21.55%vs 18.23%+15%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.